Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting

International Journal of Cardiology

Volumn 85, Issue 1, 2002, Pages 151-159

  Mulligan, Kathleen ^a   Schambelan, Morris ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

AIDS; Anabolic steroids; Androgen; Growth hormone; HIV; IGF I

Indexed keywords

ANABOLIC AGENT; ANDROGEN; GROWTH HORMONE; HORMONE DERIVATIVE; NANDROLONE DECANOATE; OXANDROLONE; OXYMETHOLONE; PEPTIDE HORMONE; SOMATOMEDIN C; TESTOSTERONE;

CACHEXIA; CANCER; CATABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; HEALTH CARE; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LEAN BODY WEIGHT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT OUTCOME; WASTING SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANABOLIC AGENTS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; TREATMENT OUTCOME; WASTING SYNDROME;

EID: 0036342194     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00247-4     Document Type: Review

References (53)

1. Slim disease: A new disease in Uganda and its association with HTLV-III infection
2. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
3. Change in the mix of AIDS-defining conditions
4. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS
5. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment
6. Relationships among nutritional status, disease progression, and survival in HIV infection
7. Weight loss as a predictor of survival and disease progression in HIV infection
8. Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome
9. Body composition studies in patients with the acquired immunodeficiency syndrome
10. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS
11. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection
12. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected patients
13. Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
14. Energy expenditure and wasting in human immunodeficiency virus infection
15. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome
16. Megestrol acetate in patients with AIDS-related cachexia
17. Megestrol acetate in patients with AIDS and cachexia
18. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery
19. Use of human growth hormone combined with nutritional support in a critical care unit
20. Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition
21. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection
22. Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial
23. Effects of recombinant human growth hormone on fat distribution in patients with HIV-associated wasting
24. Recombinant human growth hormone, insulin-like growth factor I, and combination therapy in AIDS-associated wasting: A randomized, double-blind, placebo-controlled trial
25. Prospective analysis of patterns of weight change in stage IV HIV infection
26. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients
27. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome
28. Growth hormone and other pharmacologic interventions
29. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection
30. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor-I and growth hormone
31. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - A clinical research center study
32. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men
33. Endocrine disorders in men infected with human immunodeficiency virus
34. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting
35. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy
36. A trial of testosterone therapy for HIV-associated weight loss
37. Effects of androgen administration in men with the AIDS wasting syndrome
38. Effects of testosterone replacement with a non-genital, transdermal system, androderm, in human immunodeficiency virus-infected men with low testosterone levels
39. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection
40. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels
41. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting
42. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men
43. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection
44. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss
45. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus
46. Nandrolone decanoate in HIV+ men with wasting: A randomized, double-blind, placebo-controlled study
47. Oxandrolone in AIDS-wasting myopathy
48. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss
49. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection
50. Randomized phase III trial of oxymetholone for the treatment of HIV wasting and lipodystrophy
51. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting
52. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study
53. Nandrolone decanoate increases weight and lean body mass in HIV-infected women with weight loss: A randomized, double-blind, placebo-controlled, multicenter trial